



► BSA alone	BSA-GPI, PI competitor	- BSA-GPI, No competitor	- BSA-GPI, PS competitor
+	\ \	+	₹.







	mpetitor		an competitor
BSA alone	BSA-GPI, PI competitor	BSA-GPI alone	BSA-GPI, Glycan competitor
•	.	†	1






Figure 4




Figure 5

PCT/AU2003/000944 .






Figure 6










Figure 8





PCT/AU2003/000944




Figure 10

Anti-glycan mAbs prevent murine cerebral malaria




Figure 11

19 M. C

PCT/AU2003/000944

12/24

mAb 1G7 Isotype control




Figure 12

PCT/AU2003/000944




Figure 14a




Figure 14b




Figure 14




Figure 15a




Figure 15b



Figure 15c

WO 2004/011026

PCT/AU2003/000944




Figure 15 d




Figure 15 e


WO 2004/011026

PCT/AU2003/000944


Figure 16

KLH_Glycan Conjugate


	T	T	
Glycan (ng / ug)	84	- 58	a .
Conjugation Ratio Glycan (ng / ug)	3 : 1 (molar)	191 : 1 (molar)	NA
Maleimide groups	8 moles per mole OVA	479 moles per mole KLH	17 moles per mole BSA
MW	45 000	8 000 000	67 000
Protein	OVA	KLH 8 000	BSA



PCT/AU2003/000944



Alle bil.



Molar Excess Synthetic Glycan	Percentage reduction	
0	0	
25	76	
50	89	
100	95	